trending Market Intelligence /marketintelligence/en/news-insights/trending/Kebkx_qqrGWhVmHVej8lkw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly combo treatment fails to improve overall survival in gastric cancer trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Lilly combo treatment fails to improve overall survival in gastric cancer trial

Eli Lilly and Co.'s phase 3 trial of a Cyramza and chemotherapy combination to treat gastric cancer met its main goal of extending life without the disease getting worse.

However, the treatment failed its secondary goal of improving overall survival.

The trial evaluated Cyramza, or ramucirumab, in combination with chemotherapy medicines cisplatin and capecitabine, or 5-fluorouracil, as a first-line treatment for patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma.

Lilly said it will not seek regulatory approval based on the results of this phase 3 RAINFALL trial. It also stated that the outcome of this study does not have any impact on current Cyramza approvals.

Levi Garraway, senior vice president of global development and medical affairs for Lilly Oncology, said the company hoped the positive progression-free survival outcome would have translated into an overall survival benefit but the results "highlight the challenges associated with improving outcomes for people with advanced gastric cancer."

"This is underscored by the fact that there have been no major advances over standard chemotherapy in the first-line HER2-negative gastric cancer treatment setting in the last decade," said Garraway.

In September, Lilly reported results from a phase 3 trial of Cyramza plus docetaxel, which showed improved progression-free survival in patients with urothelial cancer, a type of bladder cancer.

Cyramza was approved by the U.S. Food and Drug Administration in 2014 to treat patients with advanced gastric cancer after prior chemotherapy.